25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          SUMMARY

          Metabolically dormant bacteria present a critical challenge to effective antimicrobial therapy because these bacteria are genetically susceptible to antibiotic treatment but phenotypically tolerant. Such tolerance has been attributed to impaired drug uptake, which can be reversed by metabolic stimulation. Here, we evaluate the effects of central carbon metabolite stimulations on aminoglycoside sensitivity in the pathogen Pseudomonas aeruginosa. We identify fumarate as a tobramycin potentiator that activates cellular respiration and generates a proton motive force by stimulating the tricarboxylic acid (TCA) cycle. In contrast, we find that glyoxylate induces phenotypic tolerance by inhibiting cellular respiration with acetyl-coenzyme A diversion through the glyoxylate shunt, despite drug import. Collectively, this work demonstrates that TCA cycle activity is important for both aminoglycoside uptake and downstream lethality and identifies a potential strategy for potentiating aminoglycoside treatment of P. aeruginosa infections.

          Graphical Abstract

          Related collections

          Author and article information

          Journal
          101676030
          44856
          Cell Chem Biol
          Cell Chem Biol
          Cell chemical biology
          2451-9456
          2451-9456
          22 March 2017
          19 January 2017
          16 February 2017
          11 May 2017
          : 24
          : 2
          : 195-206
          Affiliations
          [1 ]Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA
          [2 ]Department of Biological Engineering, Institute for Medical Engineering & Science, Synthetic Biology Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
          [3 ]Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
          [4 ]Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA 02115, USA
          [5 ]Department of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912, USA
          [6 ]Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
          [7 ]Harvard-MIT Program, Health Sciences and Technology, Cambridge, MA 02139, USA
          [8 ]Department of Pediatrics, Massachusetts General Hospital, Boston, MA 02114, USA
          [9 ]Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA
          Author notes
          *Correspondence: jimjc@ 123456mit.edu
          [10]

          Present address: Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA

          [11]

          Present address: School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19014, USA

          [12]

          Present address: Vertex Pharmaceuticals, Boston, MA 02210, USA

          [13]

          Lead Contact

          Article
          PMC5426816 PMC5426816 5426816 nihpa856412
          10.1016/j.chembiol.2016.12.015
          5426816
          28111098
          99f33985-2fc6-4c68-9d90-8895e82d0cea
          History
          Categories
          Article

          Comments

          Comment on this article